REFERENCES
- Belle SH, Detre KM, Beringer KC. The relationship between outcome of liver transplantation and experience in new centres. Liver Transpl Surg. 1995;1:347–353.
- Willard CL, Liljestrand P, Goldschmidt RH, Grumbach K. Is experience with human immunodeficiency virus disease related to clinical practice? A survey of rural primary care physicians. Arch Fam Med. 1999;8:502–508.
- Heath KV, Hogg RS, Singer J, Schechter MT, O'Shaughnessy MV, Montaner JS. Adherence to clinical guidelines for the therapeutic management of HIV disease. Clin Invest Med. 1997;20:381–387.
- Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the ap-propriateness of antimicrobial therapy for bacteremia. Clin Infect Dis. 1999;29:60–66.
- Laine C, Markson LE, McKee Li, Hauck WW, Fanning TR, Turner BJ. The relationship of clinic experience with ad-vanced HIV and survival of women with AIDS. AIDS. 1998;12:417–424.
- Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311–2315.
- Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild type and mutant human immunodeficiency virus. Virology. 1998;250:255–262.
- Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. A genotypic drug resistance interpre-tation algorithm that significantly predicts therapy re-sponse in HIV-1-infected patients. Antivir Ther. 2002;7:123–129.
- Boulme R, Halfon P, Diaz R, et al. Comparative evaluation between five automated resistance interpretation algo-rithms. Antiviral Ther. 2001;6 (su ppl 1):121.
- Larder B, Wang D. Use of neural networks to define the genetic basis of HIV-1 resistance to d4T. AIDS. 2000;14\(suppl 4):S12. Abstract PL 9.5.
- Costagliola D, Descamps D, Calvez V, et al. Presence of thymidine-associated mutations and response to d4T, abacavir and ddl in the control arm of the NARVAL ANRS 088 trial. In: Program and abstracts of the Eighth Confer-ence on Retroviruses and Opportunistic Infections; Febru-ary 4–8, 2001; Chicago, IL. Abstract 450.
- Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727–736.
- Brun-Vézinet F, Race E, Descamps D, et al. Differences between genotype and phenotype in the NARVAL trial, ANRS 088. Antiviral Ther. 2000;5\(suppl 3):78. Abstract 100.
- Haubrich R, Keiser P, Kemper C, et al. CCTG 575: a random-ized, prospective study of phenotype testing (pheno) versus standard of care (SOC) for patients failing antiretroviral therapy (AR \/). In: Programs and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract 127.
- Whitcomb J, Deeks S, Huang W, et al. Reduced suscepti-bility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients. In: Programs and ab-stracts of the Seventh Conference on Retroviruses and Opportunistic Infections; February 2000; San Francisco, CA. Abstract 234.
- Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hy-persusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS. 2001;15:1125–1132.
- Haubrich RH, Kemper CA, Hellmann NS, et al., California Collaborative Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersus-ceptibility: a prospective cohort analysis. AIDS. 2002;16:F33–F40.
- Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma geno-typic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83–F92.
- Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–218.